Key insights
- PolyPid will present positive Phase 3 SHIELD II trial data for D-PLEX100 at a surgery conference. The drug showed a significant reduction in surgical site infections. While the data is promising and the drug has FDA Breakthrough Therapy designation, the company's small market cap suggests limited immediate market impact, but positive long-term potential for the stock.
PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD) announced it will present analysis of wound infection data from its Phase 3 SHIELD II trial at the Surgical Infection Society’s annual meeting on May 6, 2026, in Coronado, California.
Dr. Robert G. Sawyer, Professor and Chair of the Department of Surgery at Western Michigan University Homer Stryker M.D. School of Medicine, will deliver the presentation during the Scientific Session III from 8:00 a.m. to 9:00 a.m. PT.
The presentation will focus on ASEPSIS score data from the company’s Phase 3 SHIELD II trial of D-PLEX100. The ASEPSIS score is a clinical scoring system used to assess the severity of surgical wound infections, incorporating factors such as wound appearance, antibiotic use, drainage of pus, isolation of pathogenic bacteria, and length of hospital stay.
According to the company’s previously reported SHIELD II topline results, treatment with D-PLEX100 combined with standard care resulted in a 64% relative risk reduction in the proportion of patients with an ASEPSIS score greater than 20, compared to standard care alone. The threshold of 20 indicates clinically significant wound infection. The result showed statistical significance with p=0.0103.
D-PLEX100 is designed to provide local antibiotic activity at the surgical site to prevent surgical site infections. The product uses the company’s delivery technology to release the antibiotic doxycycline over a 30-day period following administration into the surgical site.
The Phase 3 SHIELD II trial previously demonstrated a 60% relative risk reduction in surgical site infection incidence following abdominal colorectal surgery with large incisions. D-PLEX100 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of surgical site infections in patients undergoing elective colorectal surgery.Despite the promising clinical data, PolyPid carries a market capitalization of just $87.4 million and trades at $4.58 per share. The stock has shown strong momentum with an 82% return over the last year, though InvestingPro analysis indicates the company is currently overvalued relative to its Fair Value. According to InvestingPro Tips, the company holds more cash than debt on its balance sheet but is quickly burning through cash, with levered free cash flow of negative $28 million over the last twelve months. Analysts maintain a bullish outlook with price targets ranging from $9 to $14, suggesting significant upside potential if clinical progress continues.For investors seeking deeper insights, InvestingPro offers 6 additional exclusive tips for PYPD, along with comprehensive financial health metrics and a detailed Pro Research Report covering this and 1,400+ other US equities.
The information is based on a press release statement from PolyPid.
In other recent news, PolyPid Ltd. reported a quarterly loss of $0.41 per share for Q4 2025, which did not meet the anticipated loss of $0.33 per share. This earnings miss resulted in a negative surprise of 24.24%. Additionally, PolyPid has begun the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration for D-PLEX100, aimed at preventing surgical site infections. The company has submitted the Chemistry, Manufacturing and Controls, and nonclinical sections, with the clinical section expected in the second quarter of 2026. Furthermore, PolyPid received a small business waiver from the FDA, exempting it from a $4.3 million Prescription Drug User Fee Act fee for its D-PLEX100 application. In another development, PolyPid announced it will present pharmacokinetic data from its Phase 3 SHIELD II trial at the upcoming ESCMID Global 2026 Congress. The data indicated detectable doxycycline concentrations for up to 763 hours following local application during surgery. These developments highlight PolyPid’s ongoing efforts in advancing its surgical infection drug, D-PLEX100.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.